Home Blog Page 2605

Beetles Gel Polish’s Limited-Edition Halloween Gift Box “Scream on Halloween” Makes Its Spooky Debut

NEW YORK, Sept. 2, 2025 /PRNewswire/ — Halloween is more than just trick-or-treating. It’s a tradition that lets you bring out your personality and celebrate your passions and quirks with those you love.

This year, Beetles Gel Polish, a leading nail art brand known for its high-quality products, is adding to that vibe with a very special limited-edition collection: the Scream on Halloween Gift Box. Staying true to its name, the gift box is guaranteed to spark a scream, either from fear, excitement, or both.

It’s a once-a-year collectible, only available through the end of the spooky season, making it a must-have for collectors of rare finds. Its limited-time availability will give you an edge at any Halloween party; be prepared to answer endless questions about your standout nails.

Scream on Halloween’s uniqueness makes it the perfect gift too, one that’ll make this occasion memorable for them, and linger long after the holiday ends, too.

Scream on Halloween Gift Box

The gift box comes wrapped in extremely eerie coffin-shaped holographic packaging with a layered design which dynamically switches between claw-like visuals and a church graveyard scene. It includes:

  • Nail essentials: 8 gel polishes (2 cat-eye, 1 glow-in-the-dark, 1 nail polish, base coat, top coat, 2-in-1 base & top coat, and nail glue gel) and a mini UV lamp
  • Nail tips: 2 sets (Tipex and Etch-X, 72 pieces each) for different looks
  • Creative tools: Double-ended magnet, chrome nail powder, retro nail art palette, 5 nail brushes with holder
  • Accessories: Nail stickers, charms, and a unique 2-in-1 bookmark & fridge magnet
  • Halloween extras: 7 themed temporary tattoos


Scream on Halloween: Where Gothic Meets Glam

The gift box draws inspiration from medieval gothic haunted-house aesthetics. Offering shades such as pumpkin orange, neon pink, and venom green, Scream on Halloween allows users to create looks ranging from gothic to cartoonish to mysterious. These shades are exclusive to this gift box and not sold individually.

Beetles Gel Polish’s Halloween collection goes beyond nails. It includes eye accessories to complement your costume, adding an extra layer. There’s also a church stained glass-inspired fridge magnet in the package that lets users create a gothic, spooky atmosphere when projected with a phone’s flashlight.

Where to Buy Scream on Halloween

Beetles Gel Polish’s limited-edition Scream on Halloween gift box, priced at $139.99, is now available, with supplies lasting through the end of the spooky season. Buyers can purchase either on the brand’s Official Website or Beetles Official Store on Amazon.

Beetles Gel Polish will host a giveaway of the gift box on its Instagram page during September. Make sure to stay tuned for that, or follow #BeetlesGelPolishHalloween on Instagram to get notified when it goes live.

Safe, Innovative, and Trusted Worldwide

Beetles Gel Polish’s primary focus is safety, underscored by its Leaping Bunny Certification and its dedication to developing gentle, worry-free products for users.

With innovation at its core and inspiration drawn from community trends, Beetles Gel Polish consistently delivers high-quality nail solutions. In just eight years, the brand has grown to serve over 10 million customers across more than 30 countries, earning 99% positive feedback and a 55% repeat purchase rate.

About Beetles Gel Polish

Founded in 2017 in the U.S., Beetles Gel Polish has been dedicated to empowering beauty enthusiasts of all ages to embrace boldness and express their personality. Beetles Gel Polish grow together with their community, inspiring confidence and joy, while encouraging self-expression through nail art.

Discover more at Beetlesgel.com

PRESS CONTACT

brand@beetlesgel.com 

Desilo to Launch “HARVEST™,” Encrypted Data Collaboration Platform for Healthcare, in December

SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ — Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform, HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical companies to collaborate on research without exposing sensitive patient data.

HARVEST™ by Desilo lets healthcare institutions collaborate on analysis and AI training—without ever exposing raw patient data.
HARVEST™ by Desilo lets healthcare institutions collaborate on analysis and AI training—without ever exposing raw patient data.

Medical research often requires large, multi-institutional datasets, but privacy regulations and security risks have made data sharing difficult. According to IBM, the average cost of a healthcare data breach is $10.93 million, while violations of Europe’s GDPR can trigger penalties of up to €20 million. Desilo says HARVEST™ addresses this challenge by applying Fully Homomorphic Encryption (FHE) and Federated Learning (FL) to enable joint analysis and model training while keeping raw data encrypted at all times.

The company says studies that previously took months could be completed in about a week using HARVEST™, significantly improving research efficiency. The platform supports horizontal and vertical FL, split learning, and cohort federation, while automatically managing compliance requirements under GDPR and HIPAA.

“Pharmaceutical companies and research consortia often face a tradeoff between privacy and progress,” said Seungmyung Lee, Chief Executive of Desilo. “Our mission is to shorten research timelines and reduce development costs—ultimately helping accelerate drug development and diagnoses without compromising patient privacy.”

Desilo’s technology has already drawn attention. The company won first place at iDASH, a leading global competition in privacy-preserving genomics, and has developed its own production-grade FHE library. In collaboration with U.S.-based hardware innovator Cornami, Desilo also built what it calls the world’s first commercial-scale encrypted large language model, leveraging GPU acceleration to address performance barriers in homomorphic encryption.

The startup has also been selected for several government-backed initiatives, including Korea’s National Cancer Center Safe Data Zone Project.

Desilo plans to make HARVEST™ generally available in December, with early demonstration access available through contact@desilo.ai.

Lunit Selected as Exclusive AI Partner for Spain’s Valencian Community Breast Screening Program

Milestone European deployment underscores growing global trust in Lunit’s AI for population-wide breast cancer screening

SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions have been selected as the exclusive AI tools for the breast cancer screening program of the Valencian Community, one of Spain’s largest and most progressive healthcare regions.

AI-powered breast screening launches in Spain’s Valencian Community with Lunit INSIGHT MMG and Lunit INSIGHT DBT.
AI-powered breast screening launches in Spain’s Valencian Community with Lunit INSIGHT MMG and Lunit INSIGHT DBT.

With a population of approximately 5 million, the Valencian Community is Spain’s third-largest region by population and fourth by economic size. The regional health authority has emerged as a national leader in healthtech, advancing the integration of digital health, AI diagnostics, and biomedical innovation across its public health system.

In 2024, the Valencian Community began evaluating the use of AI in its organised breast screening program, aiming to significantly increase participation from 250,000 to 400,000 women annually while maintaining high standards of care. After assessing multiple AI vendors on scientific performance, technical integration, and clinical impact, Lunit’s solutions were selected based on their ability to optimise workflows and support radiologists in delivering timely, accurate diagnoses.

The contract covers the implementation of Lunit INSIGHT MMG and Lunit INSIGHT DBT across the region and marks the company’s largest European project to date.

“The Valencian Community’s decision reflects a growing shift in how public health systems embrace AI—not as a future ideal, but as a practical solution to today’s challenges,” said Brandon Suh, CEO of Lunit. “By partnering with one of Europe’s most visionary healthcare authorities, we’re not just improving efficiency—we’re helping shape a new standard for equitable, large-scale cancer screening.”

The Valencian Community now joins a growing list of regions and countries–including Iceland, Australia, Singapore, Saudi Arabia, Qatar, and the UAE (Abu Dhabi), where Lunit’s AI is supporting public breast screening programs.

In addition to the commercial deployment, Lunit and the Valencian Community have committed to ongoing collaboration in scientific research, with plans to jointly explore new strategies for improving early cancer detection and population health outcomes.

###

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit’s FDA-cleared Lunit INSIGHT suite supports cancer screening at over 6,500 medical institutions in more than 65 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants

–        The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open until November 20; final awardees to be announced in August 2026
–        Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene’s syndromic PCR assays, instruments, and software
–        Program aims to advance Seegene’s Technology-Sharing Initiative and expand access to molecular diagnostics

SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics, announced today the launch of the 2025–2026 Nature Awards MDx Impact Grants in partnership with Springer Nature, a trusted provider to the global scientific community and the publisher of the prestigious scientific journal Nature. This year’s program will focus on antibiotic resistance in urinary tract infections (UTI-DR), one of the most pressing public health challenges worldwide.

Now in its third cycle since 2023, the program invites researchers worldwide to submit product development ideas and clinical research projects. Based on unmet clinical needs, applicants can propose up to 18 resistance genes associated with urinary tract infections as assay targets. Final awardees will receive up to USD 600,000 in research funding, along with access to Seegene’s syndromic PCR assays, consumables, instruments, and software to support the development of innovative diagnostics.

“As one of the global leading scientific publishers, Springer Nature is committed to building platforms that connect scientists and amplify innovative research,” said Richard Hughes, Vice President Publishing, Nature and Content Services, Springer Nature. “Through this program, we aim to help researchers develop diagnostic solutions that can make a difference in healthcare worldwide.”

“Seegene’s role is to provide the tools and technologies to scientists and researchers that can turn innovative ideas into real solutions,” said Dr. Jik Young Park, Vice President and Head of Seegene’s R&D Division. “In close collaboration with Springer Nature, we are fostering global research efforts by supporting scientists with both funding and access to our syndromic PCR technologies. Through these efforts, we aim to accelerate the development of molecular diagnostics that bring us closer to our vision of creating ‘a world free from all diseases.'”

The Nature Awards MDx Impact Grants are designed to complement ongoing global initiatives in diagnostics and provide researchers with resources to accelerate practical solutions. The 2024-2025 cycle supported projects focused on rapid detection of ViruResist Klebsiella pneumoniae and multiplex PCR assay for viral detection in immunocompromised patients.

About Seegene

Seegene Inc. is a global leader in molecular diagnostics with more than 20 years of expertise in research and development, manufacturing, and commercialization of syndromic real-time PCR technologies. During the COVID-19 pandemic, Seegene supplied more than 340 million tests to over 100 countries, underscoring its global impact.

Seegene’s proprietary syndromic quantitative PCR technology enables simultaneous detection of up to 14 pathogens that cause similar symptoms in a single tube. With multi-tube panel testing, it can expand coverage to dozens of clinically significant pathogens. The technology provides both co-infection status and quantitative insights, offering a unique advantage in managing complex infections.

Through its Technology-Sharing Initiative, Seegene combines its syndromic quantitative PCR technology with Seegene Digitalized Development System (SGDDS) to co-develop locally tailored diagnostic products with leading institutions and experts worldwide. By fostering global collaboration, the company advances its vision of creating “a world free from all diseases.”

Visit Seegene.com and follow us on LinkedIn (linkedin.com/company/seegene-inc).

About Nature Portfolio

Nature Portfolio’s high-quality products and services across the life, physical, chemical and applied sciences are dedicated to serving the scientific community.

Nature (founded in 1869) is the leading, international weekly journal of science. Nature Portfolio is also home to the Nature research and Nature Reviews journals, the leading open access multidisciplinary journal Nature Communications, and open access journals including Scientific Reports. Together, these journals publish some of the world’s most significant scientific discoveries.

Online, nature.com provides over nine million unique visitors per month with Nature Portfolio content, including news and comment from Nature, and the leading scientific jobs board, Nature Careers. Nature Portfolio also offers a range of researcher services, including online and in-person training and expert language and editing services. For more information, please visit nature.com and follow @Nature. Nature Portfolio is part of Springer Nature.

Press Contact: seegenekr@hoffman.com

High-Quality Urban Development Creates Policy Tailwinds, Luda Technology Group Limited (LUD.US) Well-Positioned to Benefit

HONG KONG, Sept. 2, 2025 /PRNewswire/ — The Guiding Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting High-Quality Urban Development (the “Guiding Opinions”) were recently officially released. Driven by this new policy impetus, capital markets have promptly responded with positive signals towards related industries. Among them, Luda Technology Group Limited and its subsidiaries (the “Luda Technology or “Company”, NYSE: LUD.US) saw its shares surge more than 15% in a single trading day on August 27, and continued to draw substantial market attention. As a leading enterprise in metal pipe fitting manufacturing and trading, the Company will leverage its core technologies and strategic positioning to fully capitalize on the new development opportunities presented by these policies. Luda Technology remains committed to providing high-quality products and solutions for urban infrastructure upgrades and global pipeline construction projects.

The Guiding Opinions explicitly state that China’s urbanization has transitioned from a period of rapid growth to one of stable development, with urban development entering a new phase focused primarily on improving the quality and efficiency of existing stock. The policy clearly outlines goals to enhance the comprehensive competitiveness of super-large and megacities, promote urban agglomeration integration and metropolitan area coordination in a steady and orderly manner, and support regions like the BeijingTianjinHebei region, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area in developing into world-class city clusters. Simultaneously, it aims to enhance the capacity of small and medium-sized cities and county towns, improve infrastructure and public service provision, and develop the county economy.

Within this quality-oriented new urban construction cycle, urbanization and infrastructure investment are expected to grow significantly. Particularly, natural gas pipeline projects will drive sustained increases in demand for pipe fittings. Furthermore, the mainland’s push for natural gas power generation to address coal-fired pollution issues has resulted in strong urban gas demand, further stimulating investment in natural gas-related infrastructure. According to market research reports, the global pipeline and pipe fittings market size is projected to reach approximately USD 8 billion by 2025, with an average annual growth rate of nearly 5%.

As a leading enterprise in the metal pipe fittings manufacturing industry and currently the only representative in this sector listed in the U.S., Luda Technology has been dedicated to the R&D, manufacturing, and global trade of metal pipe fittings since its establishment in 2004. With its own factory in Taian, Shandong Province, the Company primarily manufactures and sells stainless steel and carbon steel flanges and pipe fittings, while also trading steel pipes, valves, and other products. The Company has already established close cooperation with numerous petrochemical enterprises and urban pipeline projects, and utilized IPO financing to enhance its technological and R&D capabilities. After over two decades of development, the Company has built four core competitive advantages, positioning it to capture significant industry benefits from this dual policy and market-driven cycle and contribute substantially to global pipeline construction.

Luda Technology ensures exceptional quality and full-process precision control. Since 2008, the Company has introduced internationally advanced CNC machine tools, large gantry milling machines, and a full suite of testing equipment including spectrometers, ultrasonic flaw detectors, and mechanical property testers. This ensures every product leaving the factory fully complies with, and often exceeds, international standards such as ASME, DIN, EN, and JIS, as well as specific customer requirements, in terms of dimensional accuracy, material properties, sealing, and corrosion resistance. This has earned the long-term trust of leading clients in sectors like petrochemicals, electric power, and shipbuilding.

The Company possesses strong customization and flexible manufacturing capabilities. It can rapidly respond to customer-provided drawings or technical parameters to produce non-standard flanges in various specifications from DN15 to DN5000 and above, using diverse materials including carbon steel, stainless steel, alloy steel, duplex steel, and special steel. Through the application of ERP and MES systems, it has achieved digital management from order receipt to product delivery, effectively coordinating production resources and significantly shortening delivery times while guaranteeing quality.

With profound technical expertise and a commitment to continuous innovation, Luda Technology invests substantial funds annually in R&D for new materials, forging process optimization, and heat treatment technology upgrades. It has established industry-academia-research partnerships with several universities and research institutions to tackle industry technical challenges collaboratively, achieving breakthroughs in special products like ultra-low temperature flanges and highly corrosion-resistant flanges. The Company is actively pursuing an intelligent manufacturing transformation, planning to introduce automated robots and Internet of Things (IoT) technology to collect and analyze production data in real-time, continuously optimize process parameters, and enhance production efficiency and product consistency.

Luda Technology operates with a global market vision and provides localized service support. The Company possesses comprehensive export qualifications and extensive international trade experience, with products exported to numerous countries and regions across North America, Europe, the Middle East, and Southeast Asia. By establishing overseas warehouses and service centers, it can provide international customers with more timely and convenient logistics and technical support.

Mr Ma Biu, Chief Executive Officer of Luda Technology, commented, “The release of ‘The Guiding Opinions’ presents us with significant development opportunities. The next five years will be a critical period for high-quality urban development in China, and the pipeline and pipe fittings industry will usher in a new growth cycle. Leveraging the core technological advantages, stringent quality control systems, and rich international trade experience accumulated over the past two decades, Luda Technology is fully prepared to seize this market opportunity. We will continue to increase R&D investment, deepen our intelligent manufacturing transformation, provide global customers with higher quality products and services, and contribute to high-quality urban development.”

About Luda Technology Group Limited (NYSE: LUD.US)

As a manufacturer and trader of stainless steel and carbon steel flanges and fittings, Luda Technology Group Limited was found in 2004 and is headquartered in Hong Kong with a manufacturing base in Taian City, Shandong Province, China. Its history began with Luda Development Limited, and the Company is principally engaged in the trading of steel flanges and fittings. In 2005, the Company expanded its business further upstream by establishing Luda (Taian) Industrial Company Limited, which commenced the manufacturing of flanges and fittings with a self-owned factory in China. Luda Technology is principally engaged in (i) the manufacture and sale of stainless steel and carbon steel flanges and fittings products, and (ii) the trading of steel pipes, valves, and other steel tubing products. The Company’s sales network comprises customers from China, South America, Australia, Europe, Asia (excluding China), and North America and with a customer base includes manufacturers and traders from the chemical, petrochemical, maritime, and manufacturing industries.

For more information, please visit https://www.ludahk.com/en.

To find out more information, please visit our website at: https://www.ludahk.com/en.

Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data

  • Neurophet’s AI-based brain imaging analysis solutions to support global standardization of Alzheimer’s and other dementia-related data
  • Enhancing dementia research by integrating AI imaging solutions with real-world data platforms

SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer’s Disease and Other Dementias Foundation (InRAD) to accelerate global standardization of Alzheimer’s and dementia-related data.

Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data

Through this agreement, Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer’s disease and other dementias real-world data1. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation – namely, the lack of coordinated approaches – while acknowledging the wider adoption of these technologies in everyday clinical practice.

The partnership will focus on key initiatives including:

  • Enhancing clinical workflows involving MRI and PET analysis
  • Collecting and aggregating clinical imaging and quantitative data
  • Validating clinical utility of AI-based analysis solutions
  • Developing joint research and education programs

Neurophet’s flagship products — Neurophet AQUA AD, an Alzheimer’s Disease Treatment Prescription/Treatment Effect and Side Effect Monitoring Software; and Neurophet SCALE PET, a PET Image Quantitative Analysis Software; and Neurophet AQUA, a Brain MRI Analysis Software — will be available for utilization in this collaboration.

InRAD, is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer’s disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer’s Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.

Notably, InRAD has a board composed of globally renowned researchers and clinicians in the field of dementia, including Professor Philip Scheltens, a leading expert who established the MTA scale (also known as the Scheltens scale) — the world’s first MRI-based diagnostic framework for Alzheimer’s disease. Professor Scheltens commented, “Collaborations such as these help to ensure a joined-up approach, reducing barriers to real world data collection in clinical practice and supporting patient care. We are very pleased to be able to announce this MoU”.

Jake Junkil Been, Co-CEO of Neurophet, commented,

“This partnership marks a significant step toward expanding the clinical adoption and credibility of Neurophet’s AI-powered brain imaging analysis tools on a global scale. We are committed to support clinicians and researchers worldwide by enabling standardized access to high-quality Alzheimer’s disease datasets.”

Neurophet continues to lead the medical AI field by forging strategic partnerships with global healthcare stakeholders.

About Neurophet

Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software “Neurophet AQUA”, PET Image Quantitative Analysis Software “Neurophet SCALE PET”, Brain imaging treatment planning software for electric brain stimulation “Neurophet tES LAB”, Alzheimer’s Disease treatment prescription and monitoring software “Neurophet AQUA AD” for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software “Neurophet AQUA MS”.

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.

1.  Perneczky et al. Real-world datasets for the International Registry for Alzheimer’s Disease and Other Dementias (InRAD) and other registries: An international consensus, The Journal of Prevention of Alzheimer’s Disease 2025 https://doi.org/10.1016/j.tjpad.2025.100096

 

SonicStrategy Secures $40 Million USD ($55M CAD) Investment From Sonic Labs

Toronto, Ontario – Newsfile Corp. – September 2, 2025 – Spetz Inc. (CSE: SPTZ) (OTCQB: DBKSF) (doing business as SonicStrategy Inc.), the publicly traded institutional bridge to the Sonic blockchain, is pleased to announce a $40 million USD ($55M CAD) investment commitment from Sonic Labs Ltd. Sonic Labs is the foundation that oversees and develops the Sonic blockchain ecosystem. Sonic Lab’s anchor participation in the company reinforces its long-term partnership with SonicStrategy and paves the way for additional institutional capital as it intends to pursue a Nasdaq Capital Markets listing in the United States. The closing of the investment and issuance of the convertible debt instrument will occur in 5 business days, as required by the CSE policies.

The investment is structured as a convertible debt instrument funded in Sonic tokens ($S). It carries a six-month term and is convertible, at the option of the company, into common shares at a conversion price of $4.50 USD ($6.22 CAD) per common share if certain milestones are met, including the listing of the common shares of the company on the Nasdaq Capital Markets (or such other senior United States stock exchange that may be acceptable to Sonic Labs). The debt is unsecured and non-interest-bearing and any equity issued upon conversion will be subject to a three-year lock-up. This strategic capital injection sets the stage for SonicStrategy’s intended application to list its common shares on the Nasdaq Capital Markets, which is subject to regulatory approval and compliance with the listing requirements of the Nasdaq Capital Markets and United States securities laws. Capital will be used for treasury, validator operations, blockchain investments, and working capital. The key features of the debt instrument are as follows:

  • Investment Amount: $40 million USD (approx. $55 million CAD)
  • Structure: Convertible debt instrument funded with Sonic tokens
  • Term: 6 months (which may be extended by mutual agreement)
  • Conversion Price: $4.50 USD ($6.22 CAD) per common share
  • Conversion Conditions: Uplisting to Nasdaq Capital Markets with at least USD $40 million in additional funding whether through debt or equity
  • Security: Unsecured
  • Interest: Non-interest-bearing
  • Lock-Up: Three-year restriction on any common shares issued upon conversion

“The participation of Sonic Labs underscores our joint strategy to bridge the Sonic ecosystem with global capital markets,” said Mitchell Demeter, CEO of SonicStrategy. “This investment strengthens our treasury, scales our validator operations, and enables us to support early-stage Sonic-based projects. As Sonic enters a new phase of institutional and protocol-level adoption, we’re doubling down on our mission to be the leading public vehicle for long-term exposure to the network’s success.”

Under the debt instrument, the Sonic tokens provided by Sonic Labs will be locked for four years, reinforcing long-term alignment. Depending on the amount of future debt or equity capital that may be raised from any subsequent third-party financing, a portion of the principal amount of the debt instrument may be subject to a call option by Sonic Labs to further ensure strategic coordination between the two organizations. The company confirms that it has not arranged any additional debt or equity financing and any such future financing will be subject to a prior public announcement and compliance with the policies of the Canadian Securities Exchange and applicable securities laws.

“We view SonicStrategy as the natural bridge between the Sonic Network and traditional finance,” said Michael Kong, CEO of Sonic Labs. “This investment reflects our confidence in their execution and their ability to provide institutional-grade infrastructure for the Sonic ecosystem.”

This strategic alignment between Sonic Labs and SonicStrategy establishes a foundational pathway for Sonic’s public market expansion, unlocking new capital, institutional credibility, and global visibility.

The company expects to provide further updates as they become available, by way of press release, but is under no obligation to do so. There is no certainty that the company’s intended application to uplist to a senior U.S. stock exchange will be initiated or completed on any specific terms or timeline, or at all.

For more information, visit:
SonicStrategy: www.sonicstrategy.io

About Spetz Inc. (dba SonicStrategy)
Spetz Inc. (dba SonicStrategy) (CSE: SPTZ) (OTCQB: DBKSF) is the parent company of SonicStrategy Inc., a public-market gateway to the Sonic blockchain ecosystem. Spetz provides investors with compliant exposure to staking infrastructure and DeFi strategies across the Sonic network.

About Sonic Labs Inc.
Sonic is the highest-performing EVM blockchain, combining speed, incentives, and world-class infrastructure. The network achieves sub-second finality and ultra-high throughput.

At the heart of Sonic’s incentive model is Fee Monetization (FeeM), a system that lets developers earn 90% of the network fees generated by their applications. Inspired by Web2 ad-revenue sharing models, FeeM rewards developers for driving usage, growth, and real activity.

Company Contacts:
Investor Relations
Email: investors@sonicstrategy.io
Phone: 1-800-927-8745

Mitchell Demeter
Email: mitchell@sonicstrategy.io

NEITHER THE CANADIAN SECURITIES EXCHANGE, NOR THEIR REGULATION SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Note Regarding Forward-looking Statements

Certain information herein constitutes “forward-looking information” under Canadian securities laws, reflecting management’s expectations regarding objectives, plans, strategies, future growth, results of operations, and business prospects of the Company. Words such as “may”, “plans,” “expects,” “intends,” “anticipates,” “believes,” and similar expressions identify forward-looking statements, which are qualified by the inherent risks and uncertainties surrounding future expectations.

Forward-looking statements are based on a number of estimates and assumptions that, while considered reasonable by management, are subject to business, economic, and competitive uncertainties and contingencies. The Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from projected outcomes. Factors influencing these outcomes include economic conditions, regulatory developments, competition, capital availability, and business execution risks. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur, including the Company’s intention to apply to up-list its common shares on the Nasdaq Capital Markets and if such application is made, that the Company would be successful.

The forward-looking information contained in this press release represents Spetz’s expectations as of the date of this release and is subject to change. Spetz does not undertake any obligation to update forward-looking statements, except as required by law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction. None of the securities issued in the Private Placement will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.

No securities regulatory authority has either approved or disapproved the contents of this press release.

We seek Safe Harbor.

Hashtag: #SonicStrategy

The issuer is solely responsible for the content of this announcement.

Nine Moments Witnessing Liaoning’s Encounter with the World

OSAKA, Japan , Sept. 2, 2025 /PRNewswire/ — A report from China Trade News.

From August 24 to 26, the Liaoning Week of the China Pavilion at the Expo 2025 Osaka presenting the world with a grand showcase of culture, technology, trade, and green development — A presentation on the Niuheliang Hongshan Culture Site, paired with artifacts displayed through cutting-edge naked-eye 3D holography, carried audiences on a journey across 5,000 years of history. “Liaoning Premium Products” and”China Fine Gifts”, dazzled in glittering arrays. Tieling Errenzhuan, Jinzhou Shaobei martial arts, Liaoning Puppetry and acrobatic acts drew thunderous applause. The wonderful performances like Xiuyan Paper-Cutting, Qipao Show, and Knife-Carved Painting offered audiences a visual feast. Meanwhile, Liaoning enterprises joined hands with Japanese companies to explore cooperation and deepen friendship. On this global stage of the World Expo, the “Liaoning Week” unfolded through nine remarkable moments, bearing witness to Liaoning’s encounter, connection, and embrace with the world.

Over 100 guests from China and abroad have attended and witnessed the opening ceremony of the Liaoning Week.
Over 100 guests from China and abroad have attended and witnessed the opening ceremony of the Liaoning Week.